Carvolix Secures €10 Million in Funding for its Development Program

Carvolix, formerly Affluent Medical, has secured a further €10 million in funding, bringing its total development program financing to €20 million out of a target of €30 million. This funding comes from strategic shareholders, demonstrating their continued confidence. The funds will support the commercialization of Tavipilot and other regulatory and clinical projects.

To extend its cash flow beyond September 2026, Carvolix is considering venture debt financing. Currently, 2,976,190 ordinary shares will be issued at a price of €3.36 per share. Cash flow should be sufficient until that date. This financing is essential to advance key regulatory processes such as FDA approval and CE marking for Tavipilot.